Logo

Vir and GSK Report Results of VIR-7831 in P-III COMET-ICE Trial for COVID-19

Share this

Vir and GSK Report Results of VIR-7831 in P-III COMET-ICE Trial for COVID-19

Shots:

  • The IDMC has recommended stopping the enrollment in the P-III COMET-ICE trial due to evidence of profound efficacy. The study involves assessing VIR-7831 (GSK4182136) vs PBO in 583 patients for the early treatment of COVID-19 in adults at high risk of hospitalization
  • The results demonstrated an 85% reduction in hospitalization or death and were well tolerated. The ongoing trial will continue to be followed for 24wks.
  • Vir and GSK plan to submit a EUA to the FDA and for authorization in other countries. Additionally- the company also reported the results of new in vitro studies that indicate VIR-7831 maintains activity against major circulating COVID-19 variants

 ­ Ref: GlobeNewswire | Image: GSK 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions